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Background 
South Africa, the country ranked as the ‘second most stressful country to live in’ has an estimated 7 
million smokers.  A dedicated smoking cessation clinic established at Groote Schuur Hospital, Cape 
Town, provides the only clinical service and training centre in the country.  
Objectives 
To evaluate the smokers attending the clinic, in order to better understand the requirements of 
smoking cessation services in resource-limited settings. 
Methods 
Demographic and smoking-related data was collected prospectively from all clinic attendees since its 
inception. Nicotine dependence, depression scores and exhaled carbon monoxide levels were formally 
evaluated. Consent was provided to review the collected data.  
Results 
Ninety-seven smokers were evaluated. Their mean(standard deviation)age 50.9(10.9)years, and  59% 
(57/97) were male. The median age of smoking initiation was 16(interquartile range(IQR) 8 - 28) with 
a current median daily consumption of 12(IQR 7-20). Overall men smoked more than women, with a 
median of 20( cigarettes per day(IQR 10 - 20) v 12( IQR 5 - 20) respectively (p=0.001). The median 
Fagerström nicotine dependence score was 5(IQR 3 - 7), with scores of 6(IQR 4 - 8) for men and 5(IQR 
2 - 7)  for women (p=0.06); 50% of smokers had a Fagerström score <6(low to above-average 
dependence) and 22% a score of ≥8 (extreme dependence). The median Patient Health Questionnaire-
9(PHQ-9) depression score was 8(IQR 4 - 11), and 49% of smokers had symptoms of at least minor 
depression (score ≥10). The clinic could not provide pharmacotherapy. The self-reported quit rate was 
28%  at median follow up of 22 months(IQR 14 -39).  
Conclusions 
In smokers attempting to quit, moderate levels of nicotine dependence coexist with significant 
depression and anxiety symptoms. These data inform resource allocation and public health 
strategies, suggesting that in resource-limited smoking cessation services, psychological/behavioural 
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Chapter 1: Introduction 
Background 
Smoking has been identified as a risk factor for multiple poor health outcomes of which lung cancer 
was the first to be identified.[1] The impact of smoking on declining population health has been 
apparent since the early 1900s when a relationship between increased prevalence of smoking and 
increased incidence of lung cancer, previously uncommon, was identified [1, 2]. Since then multiple 
meta-analyses have highlighted relationships between smoking and non-communicable diseases 
including cardiorespiratory disease, auto-immune disease, subfertility, malignancy, cerebrovascular 
disease and poor feto-maternal outcomes. [2-6]  
South Africa’s first burden of disease report in 2000 highlighted the quadruple burden of disease the 
country faces and the need for a multifaceted approach to improving health which includes managing 
modifiable risk factors, particularly smoking [7]. 8.5% of all deaths (and 13 % of deaths in adults) are 
attributable to smoking and resulted in 3.7 to 4.3% of deaths and disability adjusted life years due to 
lung and other cancers, cardiovascular disease, COPD, TB and other medical conditions in South Africa 
in 2000.[8] 18.1% of the population was living with HIV in 2007 where there is a high incidence of TB 
for which smoking is a risk factor and is likely a factor in driving the syndemic of HIV and TB. In addition, 
both smoking and TB increase the risk of COPD. [9-12] In South Africa smokers have an increase in all-
cause mortality and in a country with a burden of TB and HIV [12]; with TB risk increased by smoking it 
is imperative that smoking cessation is central to health care. 
All-cause mortality has been shown to be 2 to 4 times higher in smokers compared to those who have 
never smoked. However, those who quit smoking successfully lower their risk with every year of 
cessation. Furthermore, those who manage to quit smoking prior to the age of 45 have the same life 
expectancy as those who have never smoked. [13]  
Impact of mass smoking cessation efforts 
The prevalence of smoking in different regions varies and is influenced by culture, levels of education, 
income and the presence of tobacco control policies.[14, 15] In sub- Saharan Africa the prevalence of 
smoking ranges from 1.8% in Zambia to 25.8 % in Sierra Leone and a prevalence of 22% in South 
Africa.[15] Sub-Saharan Africa has been described as being in stage 1 of the smoking epidemic where 
western countries have shown a decline in smoking prevalence and Sub-Saharan Africa, on the 
contrary, has illustrated a significant rise. However, amongst Sub-Saharan countries who are 
signatories to the WHO Framework Convention on Tobacco Control  and have implemented some of 
the measures necessary under this convention the smoking prevalence seems lower in those who 
implemented the Convention earlier. [15] 
The first South Africa Demographic and Health Survey (SADHS) in 1998 reported a decline in smoking 
prevalence from following implementation of Tobacco control measures in 1990, however the second 
SADHS in 2009 reflected that although the proportion of men smoking had declined, there was a 
persistently high smoking prevalence amongst women and young adults.[16] This was also reflected in 
a cross sectional study among black urban dwellers between 2008 and 2009.[17] 
The South African government has made efforts to minimise poor outcomes due to smoking with 
legislature restricting tobacco use, advertising and trade following the WHO MPOWER strategy.  
The financial benefits of smoking cessation are marked and the associated personal and societal 




Individual smoking cessation strategies 
 In populations with TB the SCIDOTS project showed that in addition to improved and sustained 
smoking cessation rates among patients who receive intervention there is the added benefit of 
reduced rates of defaulting treatment compared to those without intervention. [19]  People who stop 
smoking and those who have never smoked have an improved life expectancy and slower rate of 
deterioration of FEV1 compared to those who continue smoking.[20, 21] 
However, it is difficult to simply quit and many people will relapse and still face a negative impact on 
their health.  
Smoking cessation approaches encompass both pharmacologic and non-pharmacologic interventions 
which include motivational interviewing, counselling during routine doctor’s visits, mass advertising 
and use of nicotine replacement therapies which are all better than placebo in improving the chances 
of smoking cessation. Community based programs that support people in their efforts to quit further 
improve chances of success. [18] 
The pharmacological therapies central to smoking cessation are varenicline; most likely to assist in 
cessation, with bupropion as an alternative which tends to be more suitable to a broader patient 
profile including those with organ dysfunction (such as renal failure). Pharmacological intervention 
has been shown to be effective and strategies that combine both these approaches have been shown 
to be superior to those that employ only one or the other but there is little evidence for efficacy of 
population targeted strategies. The South African guidelines for smoking cessation reflect these 
findings[22], however, a limiting factor is that pharmacological interventions are only available at 
individuals’ expense. 
Effective smoking cessation strategies are imperative to the long-term outcomes for a variety of 
patient groups. The smoking cessation clinic that runs at Groote Schuur Hospital is the only one of its 
kind in South Africa and offers a source for investigation into effective strategies of smoking cessation 
in a resource-limited setting. 
Identifying factors which support successful quitting, and those that act as barriers, is imperative to 
the development of a successful service.  This study is aimed at assessing the socio-demographic and 
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Challenges for dedicated smoking cessation services in developing countries 
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ABSTRACT 
Background. 
South Africa, ranked as the world’s second most stressful country to live in, has an estimated 7 
million smokers. A dedicated smoking cessation clinic established at Groote Schuur Hospital, Cape 
Town, provides the only clinical service and training centre in the country. 
Objectives.  
To evaluate the smokers attending the clinic, in order to better understand the requirements of 
smoking cessation services in resource-limited settings. 
Methods.  
Demographic and smoking-related data were collected prospectively from all clinic attendees since 
its inception. Nicotine dependence, depression scores and exhaled carbon monoxide levels were 
formally evaluated. Consent was provided to review the data collected. 
Results. 
Ninety-seven smokers were evaluated. Their mean (standard deviation) age was 50.9 (10.7) years, 
and 59% (57/97) were male. The median age of smoking initiation was 16 years (interquartile range 
(IQR) 8 - 28), with a current median daily consumption of 12 cigarettes (IQR 7 - 20). Overall men 
smoked more than women, with a median of 20 cigarettes per day (IQR 10 - 20) v. 12 (IQR 5 - 20), 
respectively (p=0.001). The median Fagerström nicotine dependence score was 5 (IQR 3 - 7), with 
scores of 6 (IQR 4 - 8) for men and 5 (2 - 7) for women (p=0.06); 50% of smokers had a Fagerström 
score of <6 (low to above-average dependence) and 22% a score of ≥8 (extreme dependence). The 
median Patient Health Questionnnaire-9 (PHQ-9) depression score was 8 (IQR 4 - 11), and 49% of 
smokers had symptoms of at least minor depression (score ≥10). The clinic could not provide 





In smokers attempting to quit, moderate levels of nicotine dependence coexist with significant 
depression and anxiety symptoms. These data inform resource allocation and public health 
strategies, suggesting that in resource-limited smoking cessation services, psychological/behavioural 







The detrimental effect of smoking on population health has been apparent since the early 1900s when 
a relationship between increased prevalence of smoking and increased incidence of lung cancer, 
previously uncommon, was identified.[1,2] Since then, numerous studies have highlighted the 
relationships between smoking and non-communicable diseases including cardiorespiratory disease, 
autoimmune disease, subfertility, malignancy, cerebrovascular disease and poor fetomaternal 
outcomes.[2-6] 
 
South Africa (SA)’s first burden of disease report in 2000 highlighted the quadruple burden of disease 
the country faces and the need for a multifaceted approach to improving health that includes 
managing modifiable risk factors, particularly smoking.[7] It was reported that in SA in 2000, smoking 
accounted for 8.5% of all deaths (and 13% of deaths in adults aged >35 years) and 3.7 - 4.3% of 
disability-adjusted life-years due to lung and other cancers, cardiovascular disease, chronic obstructive 
pulmonary disease (COPD), tuberculosis and other medical conditions.[8] South Africa has an estimated 
7.2 million adults living with HIV; 60% of which are co-infected with TB, with 61% of adults on 
antiretroviral therapy.[9] In addition, both smoking and TB increase the risk of COPD. [10-13] However, 
individuals who quit smoking successfully lower their risk with every year after cessation. 
Furthermore, those who manage to quit before the age of 45 have the same life expectancy as those 
who have never smoked.[14] 
 
Many low- and middle-income countries (LMICs) have made significant efforts to minimise adverse 
health outcomes due to smoking, with legislature restricting tobacco use, advertising and trade 
following the World Health Organization (WHO) MPOWER strategy.[15] Formal cessation programmes 
mainly exist in high-income countries, which equate to ~15% of the world’s population able to access 
cessation support.[16] Very few data exist on formal cessation programmes provided in low-income 
settings or on how applicable cessation strategies developed in high-income settings are to low-
income countries.[16,17] Furthermore, smoking cessation pharmacotherapy such as nicotine 
replacement therapy (NRT), although on the WHO essential medicine list, is not always available to 
smokers.[18,19] This is particularly true in SA, where, although it is classed as a middle-income country, 
no smoking cessation pharmacotherapy is available to smokers accessing public health services. 
 
A combination of behavioural therapy and pharmacological support is regarded as the interventional 
strategy with the highest odds of long-term cessation. There are, however, no data to indicate who 
will be unsuccessful if pharmacotherapy is not added to behavioural interventions. 
 
OBJECTIVES 
A dedicated smoking cessation clinic established at Groote Schuur Hospital (GSH) in Cape Town is the 
only one of its kind in SA. Our objectives were to assess the sociodemographic and dependency 
profiles of the smokers who attended this clinic and their short- and long-term outcomes. By 
understanding the characteristics and needs of smokers in this setting, we hoped to provide relevant 
data to help guide locally applicable smoking cessation services applicable in LMICs. Identifying factors 
that support successful quitting, and those that act as barriers, are imperative in understanding the 




Establishing the clinic 
The first SA smoking cessation clinical practice guidelines were published in 2013.[19] Prior to this date 
and the establishment of the GSH clinic in December 2012, no formal smoking cessation services 
existed in the public sector. No pharmacotherapy was available for smoking cessation in the 
government hospitals, and availability of nicotine patches was very limited owing to available products 
being withdrawn from SA. With permission from the Head of the Division of Pulmonology, a 
specialised clinic was introduced to offer evaluation of and smoking cessation support to any smoker 
wishing to quit. The clinic was established within the respiratory outpatient services for convenience, 
as the trained staff were from the Division of Pulmonology and the clinic was physically near to the 
cardiology outpatients and transplant services. The doctors had received limited smoking cessation 
training at a variety of local workshops, and a nursing sister was trained to provide additional 
counselling. No specialist psychological/psychiatric support or pharmacotherapy was available in the 
clinic. 
 
The study reviewed data collected from all smokers attending GSH’s smoking cessation clinic since its 
inception. New patient data collection commenced at the clinic inception in 2012 and was truncated 
in September 2016. A pre-formed data capturing sheet to guide the consultation and to assimilate the 
required smoking cessation-specific information was used. Self-reported scales (Fagerström, Patient 
Health Questionnnaire-9 (PHQ-9), etc.) were completed by the individual person, with the remaining 
evaluation completed by the attending doctor. Information captured included age, motivation to quit, 
tobacco smoking history, medical history, Fagerström score, Wisconsin withdrawal score, PHQ-9 
depression score and perceived medication affordability. Carbon monoxide (CO) levels were tested 
using a piCO Smokerlyzer (Bedfont, UK)) at each visit. 
 
Interventions 
After completing the prespecified questionnaires, all attendees were seen by a doctor (a 
pulmonologist or medical registrar). Basic smoking history was confirmed, and level of motivation and 
reasons for wishing to quit were evaluated. Counselling was performed by the doctor, as there were 
limited alternative counselling personnel. Counselling included evaluation of previous attempts to quit 
and reasons for relapse or failure. Information on nicotine dependence was provided, as well as on 
the importance of behavioural change and pharmacotherapy if needed. Interviews were conducted in 
a motivational interviewing style directed towards behavioural change with a specific focus on self-
motivation, problem solving and strategies for coping with withdrawal symptoms. 
 
Ethical considerations 
Ethics approval to perform this clinical patient database review was granted by the University of Cape 
Town Faculty of Health Sciences Human Research Ethics Committee and GSH administration (HREC 
REF:667/205) At the time of their first visit, all patients provided written informed consent to have 
their data relevant to the smoking cessation clinic collected as part of the standard evaluation of all 
patients at the clinic. Participants also provided contact details to allow for telephonic contact to 





Data were entered onto an electronic database and independently reviewed for accuracy. Analysis 
was conducted using Graphpad prism 5.0 for Mac OSX (GraphPad Software, USA) and Stata 13 
(StataCorp, USA). Continuous data were expressed as means (standard deviations (SDs)) or medians 
with interquartile ranges (IQRs). For categorical data, the χ2 test or Fisher’s exact test was used. The 
Mann-Whitney test or Student’s t-test was used to test the association between continuous and 




The weekly smoking cessation clinic received the majority of its referrals from cardiology, respiratory 
and other tertiary clinics (organ transplant, infertility) at GSH. A few attendees were ‘healthy smokers’ 
from outside the hospital. During the audit review, 98 smokers attended for at least one visit. Only 1 
attendee did not complete the requisite forms and was not included in any of the analyses. 
Detailed characteristics of the patients attending the clinic are reported in Table 1. There was a 
predominance of male smokers (60%, 58/97). The mean (SD) age of attendees was 51.1 (10.9) years. 
There was no difference in the age of men compared with women, and the median age of smoking 
initiation was similar at 16 years (IQR 8 - 28). On average, men smoked more cigarettes per day than 
women (median 20 (IQR 10 - 20) v. 12 (IQR 5 - 20), respectively; p=0.001), resulting in higher 
cumulative total pack-years of smoking at the time of the first visit (33 (IQR 20 - 45) v. 21 (IQR 7 - 33); 
p=0.001). However, at the time of the first visit the majority of attendees were smoking 12 cigarettes 
per day on average. The most frequent motive noted for quitting was, not unexpectedly, health 
reasons (Table 2). 
 
The majority of attendees had previously tried to quit: 91% had made at least one attempt within the 
past year, with 48% making more than four attempts in the past 12 months. Only 8% reported having 
previously used pharmacotherapy in a quit attempt. Of the attendees, 68% lived with other smokers 
in the house. One-third (32%) indicated at the initial visit that they could potentially afford to purchase 
medication privately to assist with the quit attempt (Table 2). 
 
Nicotine dependence was evaluated using the Fagerström Test.[20] The median score was 6 (IQR 3 - 7). 
Women had slightly lower scores than men (median 5 (IQR 2 - 7) v. 6 (IQR 4 - 8), respectively; p=0.06), 
as shown in Table 2. However, 50% of smokers had a score of 4 - 5, indicating ‘above-average’ 
dependence, and 23% had a score >8, indicating ‘extreme dependence’ (Fig. 1). Exhaled CO levels were 
similar in men and women, with a mean (SD) score of 15.9 (9.1) parts per million. Exhaled CO 
correlated positively with current tobacco consumption (Spearman’s r=0.52 (95% confidence interval 
(CI) 0.28 - 0.70); p<0.001)) and with Fagerström scores, although less strongly (r=0.41 (95% CI 0.15 - 
0.62); p=0.02). Current number of cigarettes per day correlated strongly with the Fagerström score 
(r=0.74 (95% CI 0.62 - 0.82); p<0.001) (Fig. 2). Motivation to quit was reported as high, and there was 
no difference in in that regard between men and women. 
 
Depressive symptoms were prospectively evaluated, and complete scores were evaluable in 55 
attendees at the first visit using the PHQ-9 depression test. Nearly two-thirds (63%) of smokers 
reported at least minor symptoms of depression when screened at the first visit, and 38% (21/55) 
expressed symptoms of at least moderately severe depression (score ≥15) (Fig. 3); 18% (10/55) would 
be classified as severely depressed based on the PHQ-9 score. Evaluating the individual specified 
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subcategories making up the Wisconsin Withdrawal Scale at the initial visit (when the participants 
were still smoking), patients had on average high (>2/4) subscores for anger, anxiety and sadness 
(Table 2). 
 
Smokers who had attended the clinic were contacted by telephone in 2016/17. Using the contact 
numbers provided at the first visit, only 46 (47%) of the 97 attendees were contactable. The median 
time to follow-up was 22.5 months (IQR 14 - 39) after the first clinic visit. Based on self-reported 
smoking status, 13 attendees (28%) had successfully quit, 33 (72%) were still smoking, and 2 were 
stated to have died (cause not reported). Although the review was not specifically powered to 
evaluate predictors of outcome, individuals who had successfully quit had lower mean (SD) PHQ-9 
depression scores than those who had been unsuccessful (3.9 (1.9) v. 7.1 (1.0), respectively; p=0.046). 
In univariate analysis this translated into a trend towards successful quitting with a lower depression 
score (odds Ratio 0.86 (95% CI: 0.76;1.00; p=0.056). There was no difference in the number of clinic 
visits attended in those who quit successfully v. those who did not, nor in duration of follow-up when 
contacted. Time to first cigarette in the morning was not predictive of success, and no difference was 
seen between quitters and non-quitters with regard to baseline nicotine dependence scores 
(Fagerström score 4 v. 5; p=0.34) (Fig. 4, A and B). 
 
DISCUSSION 
Access to formal smoking cessation services is very limited in LMICs.[16] In this cohort of smokers from 
a low- to middle-income population group in SA attending a dedicated smoking cessation service, high 
levels of depressive symptoms were common, with accompanying moderate nicotine dependence. 
Currently no pharmacotherapy is provided by the government to assist smokers in quitting. Given the 
high level of depressive symptoms and stressors with relatively low nicotine dependence reported by 
the attendees, psychological and behaviour support for smokers should be a priority. The role for 
pharmacological support, given its poor availability and high cost, needs to be prospectively 
determined. Despite the lack of pharmacotherapy or specialised psychological support to assist in 
smoking cessation, some patients were successful in quitting smoking. 
 
Global smoking cessation guidelines, including the SA guidelines, recommend a combination of 
behavioural support/counselling and pharmacotherapy to support smoking cessation attempts.[19,21,22] 
The WHO has placed NRT on the essential medication list, but access to pharmacotherapy is severely 
limited and costly in resource-constrained settings, even in a high- to middle-income country such as 
SA. 
 
To date there have been very limited data published on smoking cessation clinics in LMICs. The 
majority of reports are on integrated/opportunistic brief interventions alongside healthcare 
services.[16,17] Opportunities such as tuberculosis and or HIV treatment programmes have shown 
promise as an opportunity to address tobacco smoking in conjunction with treating infectious 
diseases.[23,24] In many developed-world settings, in-hospital smoking cessation strategies have been 
an opportunity to commence interventions.[25] What is clear, however, is that if patients are not 
followed up or continued on treatment on discharge, all gains during the hospital stay with regard to 
quitting smoking are essentially for naught. 
 
SA has been characterised as the world’s second most stressful country to live in, although these data 
do not include much of Africa.[26] If one compares the level of stressors in SA to other countries 
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globally, however, Egypt (for example) is ranked 15th, Brazil 17th, China 29th, the UK 56th and 
Australia 70th. During counselling of the smokers in our study, common reported stressors included 
personal safety, financial insecurity, health concerns, community safety and anxieties regarding the 
country’s future. These concerns may be intensified by a hospitalisation or acute medical illness, 
especially if an additional financial strain and burden is precipitated by lack of income and family 
support.[27] Unexpected hospital admissions may therefore not be the best opportunities to intervene, 
given the accompanying heightened stress. 
 
Smokers in our outpatient cohort showed significant levels of background depressive symptoms, both 
on the formal PHQ-9 depression scoring and also when we evaluated the subscore of the Wisconsin 
Withdrawal Scale (while the attendees were still smoking). In active smokers, a balance exists between 
tobacco/nicotine dependence and the psychological/ behavioural habit of smoking (although these 
aspects are not always clearly separable). There is strong evidence that counselling and 
pharmacotherapy go hand in hand, with a combination generally better than either alone.[21] What is 
not clear, and has no literature to support it, is how to estimate whether an individual will be able to 
quit without the addition of medication. There is a strong correlation between Fagerström score and 
long-term cessation success,[28] and specifically time to first cigarette in the morning has been shown 
to be a simple measure to use.[28] Additionally, underlying depression and poor outcomes are 
correlated in reports from smoking cessation services.[29] In our cohort, no significant correlation was 
found between dependence indices and outcome, although the audit was not primarily powered to 
evaluate predictors of outcome owing to the nature of the study. Despite the lack of pharmacotherapy 
the long-term quit rates were encouraging, although an estimation of true success was not possible 
owing to the excessive loss to follow-up and inability to confirm smoking status chemically. What was 
evident in this cohort of low-income smokers was the low to moderate level of nicotine dependence 
and moderate to high level of depressive symptoms. This finding raises the question whether 
resources should preferably be spent on skilled counselling when establishing dedicated smoking 
cessation centres in low-income settings, or on the provision of NRT/varenicline/bupropion to aid in 
the quit attempts for all patients. 
 
Study limitations 
The study has several limitations. Referral to the service was encouraged for smokers motivated to 
quit. The service did not have on-site specialised counselling for depression or anxiety, but relied on 
referral to such services. The level of depressive symptoms may be different in individuals who are 
not willing to quit, but the characteristics of the attendees presented were of those wanting help to 
stop smoking. It was not possible to evaluate whether outcomes would be different if the patients had 
had access to pharmacotherapy. There is therefore uncertainty whether to prioritise counselling or 
medication, but the high level of depressive symptoms requires attention irrespective of smoking 
status. Follow-up was incomplete, as many of the contact telephone numbers that were provided did 
not work. Prespecified powered outcome calculations were not possible, but patient data collection 
is ongoing. 
 
Recommendations   
The questions facing the clinician with limited access to pharmacotherapy to assist smoking cessation 
are who should receive it, and whether it is possible to predict who will not be successful without the 
provision of medication. An approach could be to initiate an intensive behaviour motivation 
intervention irrespective of dependence scores, and to provide NRT at the second attempt for those 
who fail due to withdrawal symptoms. The strategy in our clinic was to provide a support service that 
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did not previously exist in an attempt to help smokers quit, and to gather the necessary data to 
motivate for locally relevant psychological and/or pharmacological interventions. Based on the data 
from this cohort, attending to the social, financial and emotional upheaval described by the majority 
of smokers seen may be of far more importance than pharmacotherapy in achieving long-term 
freedom from tobacco dependence. Poverty alleviation, sustainable income and mental health are 
not issues than can simply be solved by a nicotine patch or gum. Providing behavioural tools to assist 
with coping with life stressors, counselling and appropriate referral to social services is a starting point 
to explore in low-income settings where the behavioural aspects of tobacco dependence as a coping 
mechanism may outweigh the pure chemical addiction. 
 
As with all interventions in medicine, the certainty with which outcomes/response to therapy can be 
predicted enhances our decision-making and ability to motivate to funders to support treatment 
strategies. In low-resourced areas, the clinician is bound to equitable resource allocation and often 
provides interventions for those who will ‘benefit’ the most. If we could reasonably identify those who 
will inevitably fail without pharmacotherapy, we could motivate for such targeted interventions. 
Extrapolating from the nicotine dependence scores in this cohort, ~25% had very high dependence 
and should by any major guideline strategy have been receiving pharmacological support. The PHQ-9 
scores indicative of major depression in ~1 in 5 smokers would warrant appropriate referral to 
competent psychiatric services before any quit attempt is made. Depending on the skills of the service 
providers (doctor v. psychologist), these services could be interlinked. 
 
CONCLUSIONS 
Smoking cessation should be a priority in all healthcare services, especially in low-income settings 
where smoking results in a significant health burden, drives mortality rates and consumes substantial 
disposable income in those who can least afford it. High levels of depression and social stressors 
existed in our cohort of smokers, suggesting that interventions targeting the behavioural aspects of 
tobacco dependence should be emphasised and potentially balanced with the provision of NRT for 
those with very high dependence. Prospective, scalable and cost-effective interventions for tobacco 
dependence are needed to address this major modifiable risk factor for communicable and non-





To the E16 Staff who assisted with establishing the clinic  
 
AUTHOR CONTRIBUTIONS 
RvZS established the audit, AE,CD,RVZS,CC collected the data, MK, RVZS, GT analysed the data, All 
authors reviewed the manuscript prior to publication.  
 
FUNDING 
GYT was supported by a South African Thoracic Society-Novartis training fellowship. RVZS received 





CONFLICTS OF INTEREST 










1. Doll R, Hill AB. Smoking and carcinoma of the lung. BMJ 1950;2(4682):739-748.
https://doi.org/10.1136/bmj.2.4682.739
2. Lee PN, Forey BA, Coombs KJ. Systematic review with meta-analysis of the epidemiological
evidence in the 1900s relating smoking to lung cancer. BMC Cancer 2012;12:385. DOI 10.1186/1471-
2407-12-385
3. Forey BA, Thornton AJ, Lee PN. Systematic review with meta-analysis of the epidemiological
evidence relating smoking to COPD, chronic bronchitis and emphysema. BMC Pulm Med 2011;11:36.
DOI 10.1186/1471-2466-11-36
4. Marufu TC, Ahankari A, Coleman T, Lewis S. Maternal smoking and the risk of still birth:
Systematic review and meta-analysis. BMC Public Health 2015;15:239. DOI 10.1186/s12889-015-
1552-5
5. Fretts RC. Etiology and prevention of stillbirth. Am J Obstet Gynecol 2005;193(6):1923-1935.
DOI 10.1016/j.ajog.2005.03.074
6. Cnattingius S. The epidemiology of smoking during pregnancy: Smoking prevalence,
maternal characteristics, and pregnancy outcomes. Nicotine Tob Res 2004;6(Suppl 2):S125-S140. DOI
10.1080/14622200410001669187
7. Bradshaw D, Groenewald P, Laubscher R, et al. Initial burden of disease estimates for South
Africa, 2000. S Afr Med J 2003;93(9):682-688.
8. Groenewald P, Vos T, Norman R, et al. Estimating the burden of disease attributable to
smoking in South Africa in 2000. S Afr Med J 2007;97(8):674-681.
9. UNAIDS Aids Info  http://aidsinfo.unaids.org  (accessed 23 April 2019)
10. Wang J, Shen H. Review of cigarette smoking and tuberculosis in China: Intervention is
needed for smoking cessation among tuberculosis patients. BMC Public Health 2009;9:292. DOI
10.1186/1471-2458-9-292
11. Kwan CK, Ernst JD. HIV and tuberculosis: A deadly human syndemic. Clin Microbiol Rev
2011;24(2):351-376. 10.1128/CMR.00042-10
12. Bates MN, Khalakdina A, Pai M, Chang L, Lessa F, Smith KR. Risk of tuberculosis from
exposure to tobacco smoke: A systematic review and meta-analysis. Arch Intern Med
2007;167(4):335-342. 10.1001/archinte.167.4.335
13. Van Zyl Smit RN, Pai M, Yew WW, et al. Global lung health: The colliding epidemics of
tuberculosis, tobacco smoking, HIV and COPD. Eur Respir J 2010;35(1):27-33.
10.1183/09031936.00072909
14. Banks E, Joshy G, Weber MF, et al. Tobacco smoking and all-cause mortality in a large
Australian cohort study: Findings from a mature epidemic with current low smoking prevalence.
BMC Med 2015;13:38. DOI 10.1186/s12916-015-0281-z
15. World Health Organization. WHO Report on the Global Tobacco Epidemic, 2015. Geneva:
WHO, 2015. https://www.who.int/tobacco/global_report/2015/en/ (accessed 18 April 2019).
24 
 
16. Ward KD. Tobacco intervention research in low- and middle-income countries: Lessons 
learned and future directions. J Smok Cessat 2016;11(2):61-64. DOI 10.1017/jsc.2016.6  
17. Lando H. Promoting tobacco cessation in low- and middle-income countries. J Smok Cessat 
2016;11(2):66-69. 10.1017/jsc.2016.7  
18. World Health Organisation. Tobacco atlas online 2019. http://www.tobaccoatlas.org 
(accessed 18 April 2019).  
19. Van Zyl-Smit RN, Allwood B, Stickells D, et al. South African tobacco smoking cessation 
clinical practice guideline. S Afr Med J 2013;103(11):869-876. DOI 10.7196/samj.7484  
20. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine 
Dependence: A revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991;86(9):1119-
1127. DOI 10.1111/j.1360-0443.1991.tb01879.x 
21. Fiore MC. Treating tobacco use and dependence: 2008 update US Public Health Service 
Clinical Practice Guideline executive summary. Respir Care 2008;53(9):1217-1222.  
22. Hughes JR. An updated algorithm for choosing among smoking cessation treatments. J Subst 
Abuse Treat 2013;43(2):215-21 doi  10.1016/j.jsat.2013.01.011 
23. Khan AH, Israr M, Khan A, Aftab RA, Khan TM. Smoking on treatment outcomes among 
tuberculosis patients. Am J Med Sci 2015;349(6):505-509. DOI 10.1097/MAJ.0000000000000473 
24. Nahvi S, Cooperman NA. Review: The need for smoking cessation among HIV-positive 
smokers. AIDS Educ Prev 2009;21(3 Suppl):14-27. DOI 10.1521/aeap.2009.21.3_supp.14 
25. Rigotti NA, Clair C, Munafo MR, Stead LF. Interventions for smoking cessation in hospitalised 
patients. Cochrane Database Syst Rev 2012;5:CD001837. DOI 10.1002/14651858.CD001837.pub3 
26. Bloomberg. Most stressed out countries 2013. http://www.bloomberg.com/graphics/best-
and-worst/#most-stressed-out-countries (accessed 19 April 2019). 
27. Tanimura T, Jaramillo E, Weil D, Raviglione M, Lonnroth K. Financial burden for tuberculosis 
patients in low- and middle-income countries: A systematic review. Eur Respir J 2014;43(6):1763-
1775. DOI 10.1183/09031936.00193413 
28. Baker TB, Piper ME, McCarthy DE, et al.; Transdisciplinary Tobacco Use Research Center 
(TTURC) Tobacco Dependence Phenotype Workgroup. Time to first cigarette in the morning as an 
index of ability to quit smoking: Implications for nicotine dependence. Nicotine Tob Res 
2007;9(Suppl 4):S555-S570. https://doi.org/10.1080/14622200701673480 
29. Sonne SC, Nunes EV, Jiang H, Tyson C, Rotrosen J, Reid MS. The relationship between 
depression and smoking cessation outcomes in treatment-seeking substance abusers. Am J Addict 
2010;19(2):111-118. Doi 10.1111/j.1521-0391.2009.00015.x 
 










LIST OF FIGURES 
 
Fig. 1. Fagerström scores for nicotine dependence. (Interpretation of dependence scores: 0 - 1 low, 2 










Fig. 2. Correlation between current daily number of cigarettes smoked and Fagerström score for 
nicotine dependence. Solid line: regression line with 95% CI Spearman’s r=0.74 (95% CI 0.62 - 8.82); 
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Fig. 3. PHQ-9 depression scores. (Interpretation of PHQ-9 score: 0 - 4 no symptoms, 5 - 9 minimal 
symptoms, 10 - 14 minor depression/major depression mild, 15 - 19 major depression moderately 










Fig. 4. Characteristics of patients with known outcomes at 2 year median follow up: (A) PHQ-9 
depression score by outcome, (B) Fagerström nicotine dependence score by outcome. (Mean ±SEM)  
  



















































60%) Total (N=97) 
Current age (years), mean (SD) 48.5 (9.5) 52.4 (11.3) 50.9 (10.7) 
Age at smoking initiation (years), median 
(IQR) 
16 (15 - 19) 16 (14 - 18) 16 (14.5 - 18) 
Total years smoked, mean (SD) 31.7 (10.1) 34.7 (11.9) 33.5 (11.3) 
Average number per day smoked, median 
(IQR) 
12 (5 - 20)* 20 (10 - 20)* 20 (10 - 20) 
Current number per day smoked, median 
(IQR) 
11 (8 - 17) 15 (6 - 25) 12 (7 - 20) 
Total pack-years smoked, median (IQR) 21 (7 - 33)* 33 (20 - 45)* 29.5 (12.5 - 
40) 
Previous attempt to quit smoking, n (%) 32 (82) 43 (75) 75 (78) 
Quit attempts in the past year, n (%) 
None 3 (8) 6 (11) 9 (9) 
1 - 4 18 (46) 23 (40) 41 (43) 
>4 18 (46) 28 (49) 46 (48) 
Lives with smoker in house, n (%) 28 (72) 37 (65) 65 (68) 
Number of smokers in house, n (%) 
0 11 (28) 20 (35) 31 (32) 
1 - 2 17 (44) 21 (37) 38 (40) 
>2 11 (28) 16 (28) 27 (28) 





Table 2. Dependence and barriers to quitting smoking 
Variable Female  Male  Total 
Fagerström dependency score (n=90), 
median (IQR) 
5 (2 - 7)* 6 (4 - 8)* 6 (3 - 7) 
Exhaled CO (ppm), median (IQR) 15 (9 - 23) 14 (9 - 20) 14.5 (9 - 20) 
Motivation score (1 - 10), median (IQR)  10 (8 - 10) 10 (6 - 10)   10 (8 - 10) 
Reasons for quitting smoking, n (%) (n=98)    
Personal health 21 (54) 22 (39)  43 (44) 
Financial reasons 3 (8) 1 (2) 4 (4) 
Family 1 (3) 3 (5) 4 (4)  
Fertility 0 1 (2) 1 (1)  
PHQ-9 depression score (n=55), median (IQR) 8 (4 - 11) 8 (5 - 11) 8 (4 - 11)  
PHQ-9 total score, n (%) (n=55)     
0 - 4  9 (41) 6 (18) 15 (27) 
5 - 9  8 (36) 11 (33) 19 (35) 
10 - 15  2 (9) 9 (27) 11 (20) 
>15 3 (14) 7 (21) 10 (18) 
Wisconsin Withdrawal Scale subscore, 
median (IQR)  
   
Anger (n=87) 2.33 (1.3 - 3) 2 (1.33 - 3.3) 2 (1.3 - 3) 
Anxiety (n=90) 2.5 (1.8 - 3) 2.25 (1.3 - 2.8) 2.25 (1.25 - 3) 
Sadness (n=89) 2 (1.3 - 2.6) 1.75 (1 - 2.5) 2 (1.25 - 2.5) 
Patient could potentially afford to purchase 
medication (N=87), n (%)  
10 (28) 18 (35) 28 (32) 
IQR = interquartile range; CO = carbon monoxide; ppm = parts per million; PHQ-9 = PHQ-9 = 







Chapter 3: Appendices 
Protocol 
INTRODUCTION 
Smoking has been identified as a risk factor for multiple poor health outcomes of which lung cancer 
was the first to be identified.(1) In South Africa smokers have an increase in all-cause mortality and in 
a country with a burden of TB and HIV (2); with TB risk increased by smoking it is imperative that 
smoking cessation is central to health care. However, it is difficult to simply quit and many people will 
relapse and still face a negative impact on their health. There are multiple interventions available for 
those who are motivated to quit which include motivational interviewing, nicotine replacement 
therapy, antidepressants and nicotine receptor agonists. The smoking cessation clinic that runs at 
Groote Schuur Hospital is the only one of its kind in South Africa and offers a source for investigation 
into effective strategies of smoking cessation in a resource-limited setting. 
 Identifying factors which support successful quitting, and those that act as barriers, is imperative to 
the development of a successful service.  This study is aimed at assessing the demographic and 
dependency profile of the patients who attend this clinic and their short and long term outcomes as 
it relates to their success or failure in quitting. We hope to evaluate the success of a smoking cessation 
service in this setting and this may assist in administrative support for specific services for smoking 
cessation.   
BACKGROUND 
The impact of smoking on declining population health has been apparent since the early 1900s when 
a relationship between increased prevalence of smoking and increased incidence of lung cancer, 
previously uncommon, was identified (1, 3). Since then multiple meta-analyses have highlighted 
relationships between smoking and non-communicable diseases including cardiorespiratory disease, 
auto-immune disease, subfertility, malignancy, cerebrovascular disease and poor feto-maternal 
outcomes.   
South Africa’s first burden of disease report in 2000 highlighted the quadruple burden of disease the 
country faces and the need for a multifaceted approach to improving health which includes managing 
modifiable risk factors, particularly smoking (4). 8.5% of all deaths (and 13 % of deaths in adults) are 
attributable to smoking and resulted in 3.7 to 4.3% of deaths and disability adjusted life years due to 
lung and other cancers, cardiovascular disease, COPD, TB and other medical conditions in South Africa 
in 2000.(5) 18.1% of the population was living with HIV in 2007 where there is a high incidence of TB 
30 
 
for which smoking is a risk factor and is likely a factor in driving the syndemic of HIV and TB. In addition, 
both smoking and TB increase the risk of COPD. (2, 6-8) 
All-cause mortality has been shown to be 2 to 4 times higher in smokers compared to those who have 
never smoked. However, those who quit smoking successfully lower their risk with every year of 
cessation. Furthermore, those who manage to quit smoking prior to the age of 45 have the same life 
expectancy as those who have never smoked. (9)  
The financial benefits of smoking cessation are marked and the associated personal and societal 
benefits of smoking cessation outweigh any benefit from smoking.(10) In populations with TB , in 
addition to improved and sustained smoking cessation rates among patients who receive intervention 
there is the added benefit of reduced rates of defaulting treatment compared to those without 
intervention. (11)  People who stop smoking and those who have never smoked have an improved life 
expectancy and slower rate of deterioration of forced expiratory volume  in 1 second(FEV1) compared 
to those who continue smoking.(12, 13) 
The South African government has made efforts to minimise poor outcomes due to smoking with 
legislature restricting tobacco use, advertising and trade since 1994 in the form of the Tobacco 
Products Control Act but multiple clinical smoking cessation strategies have been identified.  
Motivational interviewing has been shown to be more effective than brief discussion during primary 
care.(14) Pharmacological intervention has also been shown to be effective and strategies that 
combine both these approaches have been shown to be superior to those that employ only one or 
the other but there is little evidence for efficacy of population targeted strategies. The South African 
guidelines for smoking cessation reflect these findings(15), however, a limiting factor is that 
pharmacological interventions are only available at individuals’ expense. 
Effective smoking cessation strategies are imperative to the long term outcomes for a variety of 
patient groups. Evaluating the only dedicated public sector smoking cessation clinic in the country is 
central to identifying strengths and weaknesses of the current efforts at assisting patients in quitting. 
It is important to identify trends in the patients who present to the clinic, those who are successful 
and what factors influence their outcome. Investigating the characteristics of the patients in this 
resource constrained clinic will be helpful in identifying whether or not intervention strategies can be 
successful without facilities that would be available in a more resource-replete setting. This will guide 
hospital administrators in determining the need for funding of smoking cessation services with regards 





What is the impact of a dedicated smoking cessation clinic, in a tertiary hospital with limited access to 
internationally accepted essential support services, in evaluating and assisting motivated patients to 
stop smoking? 
HYPOTHESIS 
Lack of access to extended counselling services and pharmacological therapy will impact significantly 
on even highly motivated patients’ ability to quit smoking regardless of their level of dependency. 
STUDY AIMS AND OBJECTIVES 
To characterize the demographic backgrounds of patients who present to the Groote Schuur Hospital 
smoking cessation clinic 
To determine the level of nicotine dependence among the patients attending the smoking cessation 
clinic 
To evaluate the need for smoking cessation medication to support quit attempts 
To determine if there is a relationship between the level of dependence and success 
To determine the proportion of participants who manage to quit smoking at the time of folder review: 
at least 3 months after first visit to the smoking cessation clinic. 
METHODOLOGY 
Study Design 
This is a cohort study of patients collected prospectively attending the Groote Schuur Hospital smoking 
cessation clinic 
Study Population and Sample 
1. The study population will consist of all adults, over the age of 18, attending the smoking cessation 
clinic at Groote Schuur Hospital from January 2013 to May 2016. 
2. The data will be collected from patient smoking cessation clinic records and electronic data 
records at Groote Schuur Hospital and the Lung Clinical Research Institute at University of Cape 
Town for the period January 2013 to May 2016 and is expected to include over 90 patients. 
3. Inclusion Criteria: Adults who smoke and attend the smoking cessation clinic 
CONSENT 
Ethical approval to perform this clinical study database review was granted by the UCT HREC 
(667/2015) and Groote Schuur Hospital administration. All patients at time of first visit signed consent 
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to have their data relevant to the smoking cessation clinic collected as part of the standard evaluation 
of all patients at the clinic. Participants also provided contact details to allow for telephonic contact 
to provide support and evaluated successful outcomes. 
CONFIDENTIALITY 
All patient records are stored in a secure access restricted storage location within the E16 respiratory 
clinic. No persons not directly involved in the Clinic have access to the clinical notes.  Electronic 
databases to allow for statistical analysis will be password restricted and all personal identifiers will 




VARIABLES AND MEASUREMENTS 
Data collection sheets and electronic databases will be used to collect the following information 






Age X   18-80 
Gender   X M, F 
Pack years X   0-150 
Level of motivation X   0-10 
Previous attempts   X Y,N 
Exhaled CO X   0-30 
Fagerstrom test  X  0-10 








 X  0-4 
Personal Health 
Questionnaire (PHQ-9) 
 X  0-11 
Smoker’s emotional index  X   
Use of drugs   X Y,N 
Use of Nicotine 
replacement therapy 
  X Y,N 
Success   X Y,N 
Method used to quit   X P,G,C,Z,E,N,S, 
Long term quitting   X Y,N 
DATA ANALYSIS PLAN  
The data will be extracted from the UCT lung institute database and stored in excel spreadsheets. 
Upon cleaning the data using Microsoft excel pivot tables, it will be exported to STATA 14 (Stata Corp, 
College Station, Texas) for analysis. Statistical tests will be performed according to whether the 
variable is continuous or categorical. Continuous data will be expressed as mean values ± SD or median 
values (IQR) depending on the normality of data. For categorical data the χ2 test or Fisher exact test 
and the Z test will be used to test for a statistical difference between variables and proportions, 
respectively. The Mann – Whitney, and Student t-test will be used to test the association between 
continuous and categorical variables. 
The age, age when started smoking, number of smoking pack.years and level of motivation will be 
reported as mean or median depending on the normality of the data and it will be analysed for  men 
and women and then for the entire population. Gender will be reported as the number of males and 
females as a proportion of the study sample. The fagerstrom scores will be reported as a frequency 
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with which each of the scores occurs. The t-test (or mann-whitney u test if data is non-parametric) will 
be used to analyse the correlation between age when started smoking and fagerstrom scores; 
Wisconsin withdrawal scores and pack years of smoking; fagerstrom scores and exhaled carbon 
monoxide. The chi squared test will be used to analyse correlation between gender and motivation to 
quit as well as gender and previous attempts to quit. 
SAMPLE SIZE CALCULATION 
The study will evaluate the whole population of patients attending the smoking cessation clinic up to 
01 June 2016. The start date will be from clinic onset date and new patient data collection will be 
truncated as at 01 June 2016.
STRENGTHS AND LIMITATIONS 
The study is the first of its kind in South Africa. It will give insight into the disadvantages and 
advantages of a smoking cessation program without the easy access to pharmacologic intervention. 
Another strength of the study is the fact that it will provide data about the demographics of patients 
who are being referred for assistance with smoking cessation and this may, in future, guide smoking 
cessation efforts at community level, primary and secondary care levels.
The patients attending the clinic are referred with the express intention of quitting smoking (as per 
clinic requirements) and will not be representative of general smokers within the community. 
Although not restricted to tertiary service patients, most patients are referred from specialist services 
such as transplant, coronary care unit and infertility clinics. This might bias the results to highly 
motivated patients and those with complex medical co-morbidities. Access to pharmacological 
support is limited strictly to patients who can afford to purchase medication themselves and thus will 
impact outcomes. Changed patient details over time may result in loss to follow up and therefore limit 
data collection. 
IMPLICATIONS 
Smoking is a well described cause of multiple causes of morbidity and mortality. It remains a leading 
cause of death in South Africa and the need for successful smoking cessation programs would have 
massive implications from a public health perspective. This research is important as it evaluates the 
only dedicated public service smoking cessation clinic in South Africa and would identify whether or 
not it is successful and why. Meta analyses have shown that more interventions are better than any 
single intervention and that the availability of medication to support cessation attempts in 
combination with counselling is more effective that counselling alone.  This research will define both 
the socio-economic characteristics but also smoking patterns and dependency of a cohort of smokers 
35 
motivated to quit smoking. It will provide important data to hospital administrators on the need for 
cessation services, and support in the form of cessation counselling and medication. This would 
support applications for funding of drugs in the public health system to allow success for more people 
and subsequently reduce the burden of disease due to smoking.   
BUDGET 
Currently there is no additional cost to carry out this research: the electronic database has already 
been set up and maintained but the Lung Clinical Research Institute at the University of Cape Town. 
Funding will be sought to allow for presentation of data at a local conference and for publication in a 
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